Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Blood drug"'
Autor:
Michael Schiff, Xianhuang Zhou, S. Kelly, J E Huffstutter, V Rodriguez-Valverde, K Bahrt, Tracy Li, C Pritchard, Patrick Durez, Mark C. Genovese, M. Le Bars
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 68, no. 11, p. 1708-1714 (2009)
Annals of the Rheumatic Diseases, Vol. 68, no. 11, p. 1708-1714 (2009)
Objective: To assess the safety, tolerability and efficacy of abatacept in patients with rheumatoid arthritis (RA) who had failed anti-tumour necrosis factor (TNF) therapy and were switched to abatacept directly or after completing washout. Methods:
Autor:
Mikołaj Teisseyre, Joanna Pawłowska, Piotr Kaliciński, Joanna Teisseyre, T Drewniak, Andrzej Kamiński, Hor Ismail
Publikováno v:
Transplantation Proceedings. 35:2292-2294
TRANSPLANT RECIPIENTS require regular administration of immunosuppressive drugs in therapeutic doses. The immunosuppressive protocols presently in use are based on therapy with 2 or 3 drugs. Cyclosporine and tacrolimus (previously termed FK-506) are
Autor:
A. Akdogan, Sedat Kiraz, Şule Apraş Bilgen, Neslihan Yilmaz, Levent Kılıç, A. A. Erbil, Umut Kalyoncu, Omer Karadag
Publikováno v:
Annals of the Rheumatic Diseases. 72:A896.2-A897
Background Leflunomide is a frequently used disease modifying drug in rheumatoid arthritis, psoriatic arthritis, vasculitis etc. Findings from animal studies have suggested that leflunomide may be a human teratogen and a wash out protocol is required
Autor:
Siddhartha Ganguly, Joseph P. McGuirk, Omar S. Aljitawi, J.D. Pipkin, Sunil Abhyankar, Anna Ludlow, Tara L. Lin
Publikováno v:
Blood. 120:4551-4551
Abstract 4551 Background: In a recent phase IIa open-label, randomized, cross-over design study, we evaluated the pharmacokinetics of Propylene Glycol-Free Melphalan (PG-free Mel) HCL and Alkeran in multiple myeloma patients undergoing transplantatio